Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.49 -0.23 (-0.47%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
32 33 Next >
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... 
Via Benzinga
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
Sanofi: Q4 Earnings Insights
  Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Sanofi SA: An Expected Move Towards The $52.90
Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news. 
Via Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform. 
Via Talk Markets
Canada Approves First Plant-Based COVID-19 Vaccine
As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic... 
Via Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline... 
Via Benzinga
A Receding tide
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient. 
Via Talk Markets
Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as... 
Via Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety... 
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
The  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Markets News for Tuesday
Oil stocks are up on huge gains. 
Via Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars
Sanofi SA's (NASDAQ: SNY)  
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.